<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046318</url>
  </required_header>
  <id_info>
    <org_study_id>262-09-004</org_study_id>
    <secondary_id>JapicCTI-090952</secondary_id>
    <nct_id>NCT01046318</nct_id>
  </id_info>
  <brief_title>A Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Long-term Study of OPC-262 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in
      patients with type 2 diabetes by repeated administration orally for 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HbA1C from baseline to each visit (OC) and Week 52 (LOCF)</measure>
    <time_frame>each visit (OC) and Week 52 (LOCF)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>every 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF)</measure>
    <time_frame>each visit (OC) and Week 52 (LOCF)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>OPC-262 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-262 5 mg will be orally administered once daily fro 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-262</intervention_name>
    <description>OPC-262 5 mg will be orally administered once daily fro 52 weeks.</description>
    <arm_group_label>OPC-262 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes patients with HbA1C above 6.5% and below 10% at both of the time of
             the 1st and the 2nd screening examinations and who have been undergoing diet and
             exercise therapies only for at least 8 weeks prior to the 1st screening examination

          2. Patients who are capable of giving informed consent

          3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient
             or the patient's partner for the entire study period and for 4 weeks after the study
             (end of the post-observation period)

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other
             specified drugs, mechanisms or diseases, and patients with gestational diabetes
             mellitus

          2. Patients with a medical history of diabetic coma

          3. Patients with poorly-controlled hypertension

          4. Patients with heart failure

          5. Patients with a complication of active hepatitis or hepatic cirrhosis

          6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy

          7. Patients with a history or complication of malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

